The utilization of letrozole at a daily dose of 10 mg for medical treatment of ectopic pregnancy considerably has a high success rate without imposing any serious side effects compared to daily 5mg letrozole.
Letrozole, an aromatase inhibitor, has recently been introduced as favorable medical treatment for ectopic pregnancy. We aimed at evaluating the effects of different doses of letrozole for induction of abortion Sixty patients with undisturbed ectopic pregnancy were classified into three equal groups. Group I: The control group that contained women who were undergoing laparoscopic salpingectomy, Group II: Patients who received letrozole (5 mg d-1) for 10 d, and Group III: Patients who received letrozole (10 mg d-1) for 10 d. After that, the human chorionic gonadotropin (β-hCG) levels were determined for the first day and after 11 d of treating. letrozole (10 mg d-1) markedly reduced the receptors of estrogen and progesterone, and subsequent vascular endothelial growth factor signals, resulting in marked apoptosis in the placenta tissue. The utilization of letrozole at a dose of 10 mg d-1 for inducement of abortion typically results in a substantial high-successful rate without any severe side effects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
laparoscopic salpingectomy
Mohamed ALI Alabiad
Zagazig, Sharqia Province, Egypt
β-hCG level
A quantitative human chorionic gonadotropin
Time frame: The β-hCG levels were assessed on the 1st of treatment
β-hCG level
A quantitative human chorionic gonadotropin
Time frame: The β-hCG levels were assessed on the 11th day of treatment
Complete blood count (CBC)
Complete blood count
Time frame: Assessed on the 1st day of treatment
Alanine Amino Transferase (ALT)
Liver enzyme
Time frame: Assessed on the 1st and 11th day of treatment
Aspartate aminotransferase (AST)
Liver enzyme
Time frame: Assessed on the 1st and 11th day of treatment
Serum creatinine
Renal function test
Time frame: Assessed on the 1st and 11th day of treatment
Blood urea
Renal function test
Time frame: Assessed on the 1st and 11th day of treatment
Complete blood count (CBC)
Complete blood count
Time frame: Assessed on the 11th day of treatment
Alanine Amino Transferase (ALT)
Liver enzyme
Time frame: Assessed on the 11th day of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Aspartate aminotransferase (AST)
Liver enzyme
Time frame: Assessed on the 11th day of treatment
Serum creatinine
Renal function test
Time frame: Assessed on the 11th day of treatment
Blood urea
Renal function test
Time frame: Assessed on the 11th day of treatment